Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 84 | ETA2022 | Next issue

44th Annual Meeting of the European Thyroid Association (ETA) 2022

Brussels, Belgium
10 Sep 2022 - 13 Sep 2022

Card image cap

Oral Presentations

Oral Session 3: Advanced Thyroid Cancer

ea0084op-03-12 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Clinicopathological and epidemiological features of thyroid cancer patients intended to initiate systemic therapy

Minaldi Elisa , Esposito Gerardo , Giani Carlotta , Valerio Laura , Agate Laura , Molinaro Eleonora , Elisei Rossella

Objectives: The majority of patients with differentiated thyroid carcinoma (TC) have an excellent prognosis, with a 5-year survival rate of 98.3%, and only rarely reaches an advanced stage of disease. The present study aims to identify the clinicopathological and epidemiological features at the time of diagnosis of a group of patients who required to be treated with systemic therapy with tyrosine-kinase inhibitors (TKI).Methods: We retrospectively evalua...

ea0084op-03-13 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Thyroid cancer relapse as a challenge to a surgeon: The efficacy of radioguided occult lesion localization (roll) technique

Czarniecka Agnieszka , Wozniak Grzegorz , Zeman Marcin , Kalemba Michal , Wygoda Zbigniew , Chmielik Ewa , Stobiecka Ewa , J. Cortez Alexander , Krajewska Jolanta , Handkiewicz-Junak Daria

Introduction: Reoperation due to recurrent or persistent thyroid cancer (TC) poses a real challenge to a surgeon who must properly estimate the benefit risk-ratio. Radioguided occult lesion localization (ROLL) technique may facilitate the localization and sufficient and safe removal of nonpalpable TC relapse.Aim: To analyze the efficacy of the ROLL technique in reoperation of TC relapse.Material and methods: A retrospective study o...

ea0084op-03-14 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Entrectinib in patients with ntrk fusion-positive (ntrk-fp) thyroid cancer: Updated data from startrk-2

W Bowles Daniel , Bazhenova Lyudmila , Hescot Segolene , Folprecht Gunnar , Daga Haruko , Massarelli Erminia , P Conley Anthony , Lamartina Livia , Lin Jessica , Ahn Eugene , Osborne Stuart , Heinzmann Sebastian , Carrizosa Daniel

Objectives: NTRK gene fusions are oncogenic drivers in many solid tumours, including thyroid cancers. In the phase 2 study STARTRK-2 (NCT02568267), entrectinib (a CNS-active tropomyosin receptor kinase [TRK] inhibitor) demonstrated efficacy in patients with NTRK-fp thyroid cancer (objective response rate [ORR]: 40%; clinical cut-off: 31 Oct 2018; n=5). We report updated data from a larger cohort with longer follow-up.Methods: A...

ea0084op-03-15 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Assessment of adrenal function in a large series of patients confirms that adrenal insufficiency is a common cause of fatigue during treatment with multikinase inhibitors (MKIS)

Colombo Carla , De Leo Simone , Giancola Noemi , Trevisan Matteo , Persani Luca , Fugazzola Laura

Background: Fatigue is one of the most frequently reported adverse events in patients treated with multikinase inhibitors (MKIs). It is present in about 59% and 24% of patients treated with lenvatinib and vandetanib, respectively, associates with a decreased quality of life and often leads to treatment discontinuation. In 2018, for the first time, a correlation between fatigue and primary adrenal insufficiency (PAI) was demonstrated in 12 patients treated with lenvatinib and v...

ea0084op-03-16 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

A clinical and molecular study of a real-world cohort of braf v600e anaplastic thyroid carcinoma treated with dabrafenib and trametinib

Nunes da Silva Tiago , Rodrigues Ricardo , Rito Miguel , Saramago Ana , Pires Carolina , Horta Mariana , Leite Valeriano , Cavaco Branca

Introduction and objectives: Anaplastic thyroid cancer (ATC) has a very low overall survival (OS) and progression free survival (PFS) due to fast growth and resistance to non-target therapies. A recent phase II study showed a dramatic increase in OS and PFS of BRAF V600E mutated ATC patients treated with Dabrafenib and Trametinib (DT). However as commonly reported in melanoma durable responses in ATC may be compromised by resistance mechanisms. Until now only a few ca...